QLGN - Qualigen Therapeutics, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Carlsbad,
United States
Type: Equity
QLGN price evolution
QLGN
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $0.4 | $2.07 | $1.35 | $4.37 |
| Short term investments | ||||
| Net receivables | $0.68 | $0.41 | ||
| Inventory | $1.56 | $1.48 | ||
| Total current assets | $1.17 | $3.45 | $4.86 | $7.54 |
| Long term investments | ||||
| Property, plant & equipment | $1.8 | $1.89 | ||
| Goodwill & intangible assets | $6.46 | $6.46 | ||
| Total noncurrent assets | $0.87 | $0.87 | $8.29 | $8.38 |
| Total investments | ||||
| Total assets | $2.03 | $4.32 | $13.15 | $15.91 |
| Current liabilities | ||||
| Accounts payable | $2.22 | $1.57 | $1.76 | $0.9 |
| Deferred revenue | $0.12 | $0.15 | ||
| Short long term debt | $1.3 | $0.83 | $2.03 | $1.77 |
| Total current liabilities | $4.14 | $5.96 | $8.49 | $8.24 |
| Long term debt | $1.17 | $1.24 | ||
| Total noncurrent liabilities | $1.35 | $1.47 | ||
| Total debt | $1.3 | $0.83 | $3.2 | $3 |
| Total liabilities | $4.14 | $5.96 | $9.84 | $9.71 |
| Shareholders' equity | ||||
| Retained earnings | -$116.8 | -$114.35 | -$110.7 | -$107.23 |
| Other shareholder equity | $0.13 | $0.17 | ||
| Total shareholder equity | -$2.1 | -$1.64 | $2.03 | $4.87 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Jan 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $0.4 | $7.04 | $17.54 | |
| Short term investments | ||||
| Net receivables | $0.54 | $0.82 | ||
| Inventory | $1.59 | $1.06 | $0.95 | |
| Total current assets | $1.17 | $10.82 | $20.8 | $6.13 |
| Long term investments | ||||
| Property, plant & equipment | $1.77 | $1.85 | $0.08 | |
| Goodwill & intangible assets | $6.47 | $0.17 | ||
| Total noncurrent assets | $0.87 | $8.26 | $2.04 | |
| Total investments | ||||
| Total assets | $2.03 | $19.08 | $22.84 | $6.69 |
| Current liabilities | ||||
| Accounts payable | $2.22 | $0.86 | $0.89 | $1.29 |
| Deferred revenue | $0.17 | $0.23 | ||
| Short long term debt | $1.3 | $1.25 | $0.13 | |
| Total current liabilities | $4.14 | $8.61 | $4.64 | $1.67 |
| Long term debt | $1.3 | $1.54 | ||
| Total noncurrent liabilities | $1.71 | $1.64 | ||
| Total debt | $1.3 | $2.55 | $1.68 | |
| Total liabilities | $4.14 | $10.32 | $6.27 | $1.67 |
| Shareholders' equity | ||||
| Retained earnings | -$116.8 | -$103.39 | -$84.74 | -$82 |
| Other shareholder equity | $0.05 | |||
| Total shareholder equity | -$2.1 | $7.24 | $16.56 | |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $1.63 | $1.61 | ||
| Cost of revenue | $1.02 | $1.26 | ||
| Gross Profit | $0.61 | $0.34 | ||
| Operating activities | ||||
| Research & development | $1.31 | $1.44 | $1.33 | $2.12 |
| Selling, general & administrative | $0.96 | $1.34 | $2.84 | $1.91 |
| Total operating expenses | $2.27 | $2.78 | $4.16 | $4.04 |
| Operating income | -$2.27 | -$2.78 | -$3.55 | -$3.69 |
| Income from continuing operations | ||||
| EBIT | -$2.22 | -$3.29 | -$3.12 | -$3.47 |
| Income tax expense | -$0 | -$0.04 | -$0.16 | |
| Interest expense | $0.24 | $0.37 | $0.38 | $0.54 |
| Net income | ||||
| Net income | -$2.45 | -$3.66 | -$3.46 | -$3.85 |
| Income (for common shares) | -$2.45 | -$3.66 | -$3.46 | -$3.85 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Jan 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $4.98 | $5.65 | $2.85 | |
| Cost of revenue | $4.3 | $4.33 | ||
| Gross Profit | $0.68 | $1.32 | $0.21 | |
| Operating activities | ||||
| Research & development | $5.21 | $6.84 | $11.72 | |
| Selling, general & administrative | $6.1 | $11.79 | $12.27 | |
| Total operating expenses | $11.3 | $22.86 | $23.98 | $10.73 |
| Operating income | -$11.3 | -$22.18 | -$22.66 | |
| Income from continuing operations | ||||
| EBIT | -$11.9 | -$18.88 | -$17.93 | |
| Income tax expense | -$0 | -$0.27 | $0.01 | |
| Interest expense | $1.52 | $0.03 | -$0.04 | -$0.05 |
| Net income | ||||
| Net income | -$13.42 | -$18.64 | -$17.9 | -$19.55 |
| Income (for common shares) | -$13.42 | -$18.64 | -$17.9 | |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | -$2.45 | -$3.66 | -$3.46 | -$3.85 |
| Operating activities | ||||
| Depreciation | $0 | -$0.24 | $0.12 | $0.12 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $0.07 | $0.12 | $0.65 | $0.25 |
| Total cash flows from operations | -$5.67 | $0.93 | -$2.93 | -$2.63 |
| Investing activities | ||||
| Capital expenditures | $0.25 | -$0.05 | -$0.2 | |
| Investments | ||||
| Total cash flows from investing | $0.24 | $4.23 | -$0.05 | -$0.2 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | -$0.11 | -$0.44 | ||
| Total cash flows from financing | -$0.11 | -$0.44 | ||
| Effect of exchange rate | -$0.12 | -$0.04 | $0.16 | |
| Change in cash and equivalents | -$5.55 | $4.72 | -$2.98 | -$2.83 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Jan 2021 |
|---|---|---|---|---|
| Net income | -$13.42 | -$18.64 | -$17.9 | |
| Operating activities | ||||
| Depreciation | $0 | $0.38 | $0.34 | |
| Business acquisitions & disposals | $0.14 | |||
| Stock-based compensation | $1.1 | $5.48 | $5.29 | |
| Total cash flows from operations | -$10.3 | -$13.25 | -$14.73 | |
| Investing activities | ||||
| Capital expenditures | -$0.32 | -$0.13 | ||
| Investments | ||||
| Total cash flows from investing | $4.22 | -$0.18 | -$0.14 | -$0.07 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | -$0 | $8.82 | ||
| Net borrowings | -$0.55 | $2.9 | -$0.14 | |
| Total cash flows from financing | -$0.55 | $2.91 | $8.43 | $34.05 |
| Effect of exchange rate | $0.02 | |||
| Change in cash and equivalents | -$6.64 | -$10.52 | -$6.44 | $23.82 |
News
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | N/A |
| Revenue | $3.23M |
|---|---|
| EBITDA | -$12.09M |
| EBIT | -$12.10M |
| Net Income | -$13.42M |
| Revenue Q/Q | -100.00% |
| Revenue Y/Y | -35.10% |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | -151.55% |
| ROE | -1.70K% |
| Debt/Equity | -1.97 |
|---|---|
| Net debt/EBITDA | -0.31 |
| Current ratio | 0.28 |
| Quick ratio | 0.28 |